VirTech Bio

Founded with a vision to revolutionize healthcare research, VirTech Bio is dedicated to developing cutting-edge technology for medical applications. Their core mission is to provide innovative solutions that address critical needs in healthcare, particularly in trauma and transplantation. The company's flagship product, OxyBridge™, is an advanced human-derived hemoglobin-based oxygen carrier (HBOC) designed for use in hemorrhagic shock and donor organ transplants, offering a vital alternative when blood transfusion is not an option. VirTech Bio primarily targets the medical and healthcare sectors, focusing on both military and civilian applications.

VirTech Bio has garnered attention from notable figures in the healthcare and biotech industries, although specific names of affiliated people and investors are not disclosed. The introduction of OxyBridge™ marks a significant achievement, positioning the company as a leader in the development of life-saving medical technologies. With its innovative approach, VirTech Bio aims to significantly reduce mortality rates associated with blood loss and improve outcomes in organ transplantation, thereby making a substantial impact on global healthcare.